基本信息
浏览量:3
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Despite advances in immune-based therapies for other types of cancer, this approach thus far has been ineffective for many pediatric cancers, especially solid tumors. My research focus lies in understanding the adoptive resistance mechanisms that enable tumor immune evasion in pediatric cancer, and rationally investigating how we can overcome these challenges with targeted immunotherapy.
With an interest in harnessing the immune system to continue to improve outcomes for patients whose disease has not been cured with available treatment modalities, during my pediatric hematology/oncology fellowship at the joint Johns Hopkin/NCI program I sought out a project to understand the principles of the tumor microenvironment. Under the mentorship of Dr. Drew Pardoll and Dr. Nicolas Llosa, my research elucidated immunosuppressive mechanisms present within the tumor microenvironment which prevent metastatic osteosarcoma from being recognized and destroyed by the immune system. Through this process, I gained expertise in a wide array of basic science techniques, including tumor processing, immunohistochemistry and digital image analysis, laser-capture microdissection, RNA extraction from tumor tissue, RNA seq, transcriptomic analysis, multiparameter flow cytometry, and intracellular cytokine secretion assays, amongst other methodologies. To solidify my expertise in the management of patients with sarcomas, I undertook a senior fellowship in Pediatric Sarcoma from 2018-2020 at Johns Hopkins. This experience complemented my research interests and enabled me to understand the complexity of patients with relapsed/refractory solid tumors who may present for immunotherapy-based clinical trials.
To consolidate my interest in translational research, I shifted gears to work on clinical implementation of laboratory efforts. Thus, I pursued a senior Pediatric Immunotherapy fellowship at the National Cancer Institute under the mentorship of John Glod and Nirali Shah. I am gaining experience in clinical trial design and toxicity management of novel immunotherapies, with a specific focus on cell therapy. My laboratory-based experiences have further prepared me well to incorporate meaningful bench-to-bedside, and bedside-to-bench correlative studies into these trials. I am the Lead Associate Investigator (LAI) for an upcoming phase 1/2 CAR T cell trial, which should open in 2021.
研究兴趣
论文共 64 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
TRANSPLANTATION AND CELLULAR THERAPYno. 2 (2024): 155-170
John A Ligon,Paul Castillo, Xiaojie Ma,Linchun Jin,Haipeng Tao,Duy Nguyen, Gabriel Jobin,Olga Guryanova,Jatinder K Lamba, W Greg Sawyer,Duane Mitchell,Hector Mendez-Gomez,
Transplantation and Cellular Therapyno. 2 (2024): S178-S179
John A. Ligon, Margaret C. Cupit-Link, Christine Yu,Jennifer Levine, Toni Foley,Seth Rotz, Akshay Sharma,Veronica Gomez-Lobo,Nirali N. Shah
Transplantation and Cellular Therapy (2024)
Journal of Clinical and Translational Scienceno. s1 (2024): 110-110
Joanna Theophilopoulos, Rebekah King, Autumn Citta, Constance Alford, Natalie Dotson,Connie Cañete-Gibas,Carmita Sanders,Nathan Wiederhold,John A. Ligon,Connie Trieu
BMC Infectious Diseasesno. 1 (2024): 1-7
Reema Kashif,Biljana Horn,Jordan Milner,Michael Joyce,Mansi Dalal, Jin-Ju Lee,Kevin McNerney, Jessica Cline,John Fort,Paul Castillo, Jorge Galvez,Warren Alperstein,
Pediatric transplantationno. 4 (2024): e14784-e14784
Jianping Huang, Haipeng Tao,Dongjiang Chen,Changlin Yang,Duy Nguyen,Ruixuan Liu, Tianyi Liu, Avirup Chakraborty,Alicia Hou, Nicole Petit, Muhammad Abbas, Christina Roemeling,
crossref(2024)
Clinical Cancer Researchno. 18_Supplement (2023): PR08-PR08
Transplantation and cellular therapyno. 2 (2023): 155-170
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn